| Withdrawn | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in NCT02587871 | University of Southern California | Phase 2 |
| Unknown | INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIEN NCT03955848 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Active Not Recruiting | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT02159495 | City of Hope Medical Center | Phase 1 |
| Completed | Nivolumab in AML in Remission at High Risk for Relapse NCT02532231 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hema NCT02122081 | Sumithira Vasu | Phase 1 |
| Completed | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies NCT02396134 | City of Hope Medical Center | Phase 2 |
| Unknown | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Ch NCT02071901 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Le NCT01885689 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Terminated | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant NCT02038153 | Albert Einstein College of Medicine | Phase 1 / Phase 2 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treatin NCT01707004 | University of Wisconsin, Madison | Phase 2 |
| Completed | PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant NCT01841333 | University of Colorado, Denver | Phase 2 |
| Terminated | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia NCT01801046 | University of Southern California | Phase 1 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With NCT01519596 | Wake Forest University Health Sciences | N/A |
| Completed | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leuk NCT01839240 | University of Chicago | Phase 1 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission NCT01842139 | University of Chicago | Phase 1 |
| Terminated | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission NCT01465386 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemother NCT01307579 | Children's Oncology Group | Phase 3 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previ NCT01235572 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My NCT01260714 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Completed | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematolo NCT01175785 | Nohla Therapeutics, Inc. | Phase 2 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Completed | Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia NCT01024127 | Children's Oncology Group | — |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Pa NCT00860574 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease NCT00863434 | University of Washington | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia NCT02144675 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Dono NCT00589316 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treat NCT00540995 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With NCT00322101 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Tran NCT01056614 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia NCT00093418 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission NCT00093470 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Cilengitide in Treating Patients With Acute Myeloid Leukemia NCT00089388 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Mye NCT00070135 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete NCT00045396 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary A NCT00045435 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in NCT00093743 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemi NCT00004918 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patie NCT00005940 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating NCT00003875 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |
| Withdrawn | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant NCT02723435 | Stanford University | Phase 2 |